Despite advances in surgical techniques, radiotherapy, and systemic therapies, including targeted therapies for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) driver mutations, the prognosis for many patients with NSCLC has remained poor, with 5-year survival rates often below 20% [3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.